Teleflex Incorporated (TFX)

Teleflex's stock has trended down by 38.73% in the past six months. As of July 16, 2025, the share price was $113.32, a 50.79% decline from July 17, 2024. Recent events include Q1 2025 earnings call where revenues decreased by 5% year-over-year, the acquisition of BIOTRONIK's Vascular Intervention Business, FDA clearance for AC3 Range Intra-Aortic Balloon Pump, and expansion of indications for QuikClot Control+. Analyst ratings have been adjusted with a consensus rating of "Hold" and an average price target of $159.63. Teleflex declared a quarterly dividend of $0.34, paid on June 16, 2025.

Teleflex anticipates a stable procedure environment with seasonality in line with pre-pandemic levels for 2024. The company's portfolio, focused on critical care procedures, is not expected to benefit from pent-up demand. Utilization continued to return towards normal seasonality during Q4 2023. The company's revenue vulnerability is evident in its dependence on healthcare market fluctuations, with 85.4% of total revenue derived from medical device segments. Supply chain dynamics largely stabilized through 2023, with continued improvements expected in 2024.

Teleflex, Inc. is a global provider of medical technology products, focusing on the design, development, manufacturing, and supply of single-use medical devices used in critical care and surgical applications. The company operates within the Health Technology sector and the Medical Specialties or Medical Equipment/Instruments industry. Its product portfolio includes vascular access, interventional, anesthesia, surgical, interventional urology, general urology, emergency medicine, and OEM and development services.

Teleflex has a global presence, distributing its products in over 150 countries. It operates through four primary segments: Americas, EMEA, Asia, and OEM. The United States accounts for approximately 60% of its revenue, with international markets making up the remainder. Teleflex also operates manufacturing facilities in the Czech Republic, Malaysia, Mexico, and the US.

Teleflex has maintained a strong brand reputation, being named a MedReps.com 2023 Best Places to Work for large companies for the sixth consecutive year. The company published its 2024 Global Impact Report, highlighting its commitment to the healthcare industry. The company's medical device reliability ratings are reported as 4.7/5 from healthcare professionals. A legal firm encouraging those who suffered losses in Teleflex stock to contact them appeared in news headlines, but this does not necessarily indicate a direct negative impact on the company's operational brand reputation.

Teleflex has significant institutional ownership, with 1026 institutional owners and shareholders holding a total of 64,505,512 shares, representing approximately 89.9% to 93.36% of the company's stock. Major institutional owners include T. Rowe Price Investment Management, Inc., BlackRock, Inc., and Vanguard Group Inc. Individual investors and public companies hold the remaining shares, with individuals accounting for approximately 0.39%.